Ligand Pharmaceuticals and PhoreMost have announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target.
Dassault Systèmes has signed an agreement to acquire US-based Medidata Solutions for an enterprise value of $5.8bn (£4.5bn).
Following the success of their ongoing alliance, Boehringer Ingelheim and the University of Dundee extend their collaboration to develop new medicines that target and destroy key cancer causing proteins.
AptarGroup has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical, for a combined enterprise value of approximately $50m (£39.3m).
Merck has signed an agreement to acquire biopharmaceutical firm Tilos Therapeutics in a deal valued at around $773m (£608m).
nference, a leader in knowledge synthesis software solutions for the life sciences industry, today announced a multi-year alliance with Janssen Research & Development, LLC that will leverage the nference artificial intelligence (AI) platform to create a unified data science-powered connective fabric across the Janssen R&D organization.
Vertex Pharmaceuticals has signed an agreement to acquire US-based Exonics Therapeutics in a deal valued up to $1bn (£787m).
Lantheus Holdings has collaborated with NanoMab Technology to provide a novel biomarker for clinical development and management of immuno-oncology therapies.
Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity.
Juvenescence, a life sciences company developing therapeutics and technologies to treat diseases of aging and increase human longevity, is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.